Loading...
XETRGME
Market cap19mUSD
Dec 23, Last price  
3.50EUR
1D
2.34%
1Q
-19.72%
Jan 2017
-70.24%
Name

Geratherm Medical AG

Chart & Performance

D1W1MN
XETR:GME chart
P/E
17.05
P/S
0.85
EPS
0.21
Div Yield, %
4.29%
Shrs. gr., 5y
1.80%
Rev. gr., 5y
0.71%
Revenues
22m
-13.73%
7,735,1288,459,6728,589,6138,802,00310,734,56414,914,43617,783,09718,981,11116,280,27617,029,04018,714,64121,588,89522,062,98421,030,77921,521,92019,851,17627,466,23024,638,67325,850,61922,300,873
Net income
1m
+8.57%
1,332,7051,426,91900-2,920,6172,678,5452,542,2901,095,1151,194,1901,333,7811,682,3592,701,2652,236,805679,7871,153,595289,8572,045,328332,6471,023,4461,111,156
CFO
1m
-45.09%
871,000860,000240,9201,038,620473,0002,710,000427,0001,063,0001,605,0002,438,000952,0003,774,000792,0002,466,0001,347,0001,540,0003,915,000917,0002,606,0001,431,000
Dividend
Aug 19, 20240.1 EUR/sh

Profile

Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infections, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.
URL
https://www.geratherm.de
IPO date
Jul 03, 2000
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
22,301
-13.73%
25,851
4.92%
24,639
-10.29%
Cost of revenue
19,943
25,717
14,552
Unusual Expense (Income)
NOPBT
2,357
134
10,087
NOPBT Margin
10.57%
0.52%
40.94%
Operating Taxes
645
631
(25)
Tax Rate
27.38%
471.77%
NOPAT
1,712
(497)
10,112
Net income
1,111
8.57%
1,023
207.67%
333
-83.74%
Dividends
(813)
(653)
(1,980)
Dividend yield
Proceeds from repurchase of equity
(233)
4,207
BB yield
Debt
Debt current
3,237
3,474
3,123
Long-term debt
7,231
9,295
6,721
Deferred revenue
1,429
1,515
Other long-term liabilities
2,880
252
1,289
Net debt
2,097
1,021
6,210
Cash flow
Cash from operating activities
1,431
2,606
917
CAPEX
(758)
(2,739)
(1,270)
Cash from investing activities
(2,307)
(985)
3
Cash from financing activities
(2,835)
4,749
(3,525)
FCF
4,563
(5,681)
9,392
Balance
Cash
7,745
10,886
6,470
Long term investments
626
862
(2,836)
Excess cash
7,256
10,455
2,402
Stockholders' equity
5,852
4,604
6,428
Invested Capital
25,895
32,799
26,304
ROIC
5.83%
38.83%
ROCE
7.40%
0.36%
35.12%
EV
Common stock shares outstanding
5,412
5,445
4,950
Price
Market cap
EV
EBITDA
2,359
1,610
11,802
EV/EBITDA
Interest
153
179
143
Interest/NOPBT
6.49%
134.16%
1.42%